{"id":"dosing-of-enoxaparin-for-vte-prophylaxis","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Injection site hematoma"},{"rate":"1-3","effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. It is used for venous thromboembolism (VTE) prophylaxis to prevent deep vein thrombosis and pulmonary embolism in at-risk patients.","oneSentence":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:21.370Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis in surgical patients"},{"name":"Venous thromboembolism prophylaxis in medically ill patients"},{"name":"Treatment of acute deep vein thrombosis"},{"name":"Treatment of acute pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT06025162","phase":"","title":"Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma","status":"UNKNOWN","sponsor":"Methodist Health System","startDate":"2023-07-21","conditions":"Thromboembolism, Venous","enrollment":100},{"nctId":"NCT01916707","phase":"PHASE4","title":"Weight Based Enoxaparin in Trauma Patients","status":"UNKNOWN","sponsor":"Intermountain Health Care, Inc.","startDate":"2013-07","conditions":"Venous Thromboembolism","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":125,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dosing of enoxaparin for VTE prophylaxis","genericName":"Dosing of enoxaparin for VTE prophylaxis","companyName":"Intermountain Health Care, Inc.","companyId":"intermountain-health-care-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism prophylaxis in surgical patients, Venous thromboembolism prophylaxis in medically ill patients, Treatment of acute deep vein thrombosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}